Drug Profile
Research programme: thymopentin - mondoBIOTECH
Alternative Names: DasKloster 0112-01; DK-0112; TP 5 - Mondobiotech; TP-5Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Sarcoidosis
Highest Development Phases
- No development reported Sarcoidosis
- Discontinued Lung disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Sarcoidosis in Switzerland
- 09 Mar 2011 Research programme: thymopentin - mondoBIOTECH is available for licensing as of 09 Mar 2011. http://www.mondobiotech.com
- 04 Feb 2011 Research programme: thymopentin - mondoBIOTECH receives Orphan Drug status for Sarcoidosis in USA